Like Aptuit, Inc.

closed 8/16/2017 via BusinessWire

Evotec BioSystems GmbH, acquired Aptuit, Inc.

synopsis: Evotec announced that it has successfully completed the acquisition of Aptuit, a partner research organisation for integrated outsourced drug discovery and development solutions. This acquisition adds considerable business opportunities to further accelerate Evotec's long-term strategy to be the industry partner of choice for external innovation.
buyer: Evotec BioSystems GmbH (XTRA:EVT:$226.46)
Founded in Hamburg Germany, Evotec BioSystems GmbH is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. "
target parent: Welsh, Carson, Anderson & Stowe
target: Aptuit, Inc.
Aptuit, Inc. (formerly Global Pharmaceutical Development, Inc.) is an emerging company focused on streamlining and supporting the drug development process for biotechnology and pharmaceutical innovators.
price ($mm)
$300
rev ($mm)
$93
EBITDA ($mm)
$12
EV / rev
3.2x
EV / EBITDA
25.8x
announced 9/25/2017 via BusinessWire

Konica Minolta, Inc., will acquire Invicro, LLC

synopsis: Konica Minolta, Inc. and Boston-based Invicro LLC announced that they have concluded an agreement whereby Konica Minolta will acquire Invicro, a leading provider of imaging services and software for research and drug development.
buyer: Konica Minolta, Inc. (TSE:4902:$9,557.68)
Konica Minolta, Inc. is a Japanese technology company headquartered in Tokyo. The company manufactures business and industrial imaging products, including copiers, laser printers, multi-functional peripherals (MFPs) and digital print systems for the production printing market. "
target: Invicro, LLC
Invicro is a leading provider of imaging services and software for research and drug development. Headquartered in Boston, Massachusetts, Invicro LLC was founded in 2008 with the mission of improving the role and function of imaging in drug discovery and development across all therapeutic areas.
price ($mm)
rev ($mm)
$106
EBITDA ($mm)
$17
EV / rev
0.0x
EV / EBITDA
0.0x
announced 6/20/2017 via Company Press Release

Pamplona Capital Management LLP, will acquire PAREXEL International Corporation

synopsis: Pamplona Capital Management, LLP has entered into a definitive agreement to acquire all of the outstanding shares of PAREXEL International Corporation, a leading global biopharmaceutical services provider. PAREXEL provides a broad range of expertise-based clinical research, consulting, medical communications, and technology solutions and services.
buyer: Pamplona Capital Management LLP
Pamplona Capital Management is a London, New York, and Boston-based specialist investment manager established in 2005 that provides an alternative investment platform across private equity, fund of hedge funds, and single-manager hedge fund investments. "
target: PAREXEL International Corporation (PRXL:$1,939.36)
PAREXEL International Corporation is a leading global biopharmaceutical services company, providing a broad range of clinical research, consulting, medical communications, and technology solutions and services to the worldwide pharmaceutical, biotechnology and medical device industries.
price ($mm)[EV]
$4,508 [$4,923]
rev ($mm)
$2,097
EBITDA ($mm)
$343
EV / rev
2.4x
EV / EBITDA
14.6x
announced 5/10/2017 via BNC Analysis

inVentiv Health, Inc. will be merged with INC Research, Inc.,

synopsis: INC Research Holdings, Inc., a leading global Phase I-IV Contract Research Organization ("CRO"), and inVentiv Health, Inc., a leading, global CRO and Contract Commercial Organization will merge. INC Research shareholders will own approximately 53 percent and inVentiv shareholders will own approximately 47 percent of the merged entity.
buyer: INC Research, Inc. (SYNH:$3,472.40)
INC Research is a leading global contract research organization ("CRO") providing the full range of Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. "
target parent: Thomas H. Lee Partners, L.P.
target: inVentiv Health, Inc.
inVentiv Health is a global professional services organization designed to help the biopharmaceutical industry accelerate the delivery of much-needed therapies to market. Their Clinical Research Organization (CRO) and Contract Commercial Organization (CCO) offer a differentiated suite of services.
price ($mm)[EV]
$2,453 [$4,552]
rev ($mm)
$2,156
EBITDA ($mm)
$306
EV / rev
2.1x
EV / EBITDA
14.9x
closed 10/3/2016 via BusinessWire

Quintiles Transnational Corp. merged with IMS Health Incorporated,

synopsis: Quintiles IMS Holdings, Inc. announced that it has successfully completed its merger of equals transaction between IMS Health Holdings, Inc. and Quintiles Transnational Holdings Inc. The merger creates a leading information and tech-enabled global healthcare service provider, and a full suite of end-to-end clinical and commercial offerings.
buyer: IMS Health Incorporated (NYSE:IQV:$10,412.00)
IMS Health is a leading global information and technology services company providing clients in the healthcare industry with end-to-end solutions to measure and improve their performance. They connect configurable SaaS applications to complex healthcare data in the IMS One™ cloud platform. "
target: Quintiles Transnational Corp. (Q:$4,497.17)
Quintiles is the world’s largest provider of biopharmaceutical development services and commercial outsourcing services. They help customers navigate the increasingly complex healthcare environment to improve efficiency and to deliver better healthcare outcomes.
price ($mm)
$8,750
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 11/6/2009 via BusinessWire

PPD, Inc., acquired Excel PharmaStudies Inc.

synopsis: PPD, Inc. announced it has completed its acquisition of Excel PharmaStudies, Inc., one of the largest contract research organizations in China. The acquisition strengthens PPD’s full range of drug development services in the country and positions it to capitalize on the tremendous growth of the outsourcing market in Asia Pacific.
buyer: PPD, Inc.
PPD is a leading global contract research organization (CRO) providing discovery, development and post-approval services as well as compound partnering programs. PPD's clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. "
target: Excel PharmaStudies Inc.
Excel PharmaStudies, Inc. is a full-service provider of clinical research, registration, biometrics, and training and consultation services. Excel is the leading CRO in China and operates 22 offices worldwide, with more than 300 staff members.
price ($mm)
$16
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 7/17/2009 via PR Newswire

Pierrel SpA, purchased US Operations from Encorium Group Inc.

synopsis: Encorium Group, Inc., a full service multinational clinical research organization, announced that is has completed the previously announced sale of the Company's U.S. business to Pierrel Research USA, Inc., a wholly-owned subsidiary of Pierrel SpA, an international contract research organization listed on Milano's Stock Exchange.
buyer: Pierrel SpA (PIELF:$0.00)
Pierrel S.p.A. is a pharmaceutical company specializing in contract research, development and the manufacture of medicines. The Pierrel Group boasts over 50 years of experience in the pharmaceutical sector, and is one of the main Italian manufacturers of local anaesthetics for dental use. "
seller: Encorium Group Inc.
Encorium is a full-service Contract Research Organization providing comprehensive solutions for pharmaceutical, biotechnology, and medical device companies. At Encorium we recognize the challenges that often arise during drug development.
price ($mm)[EV]
$0.08 [$2.58]
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 4/8/2009 via PR Newswire

Next Fuel, Inc., will acquire Clinical Trials of the Americas, Inc.

synopsis: Clinical Trials of America Inc. announced that it has entered into a binding letter of intent to sell shares equal to approximately 75% of its issued and outstanding shares to Next Fuel Inc., a developer of a proprietary "On Demand" Hydrogen Generation System.
buyer: Next Fuel, Inc.
Next Fuel Inc. is a developer of a proprietary "On Demand" Hydrogen Generation System that is used as fuel for Fuel Cells which produce electricity. "
target: Clinical Trials of the Americas, Inc.
Clinical Trials of the Americas, Inc. provides clinical trial investigator services in dedicated sites throughout the Americas. Initially, we intend to introduce our services in Central America.
price ($mm)
$0.29*
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 3/2/2009 via PR Newswire

ASG, Inc., acquired Ockham Development Group, Inc.

synopsis: ASG, Inc. a high-quality functional outsourcing and specialty staffing services group based in Cary, North Carolina - has acquired neighboring Ockham Development Group, Inc., a full-service contract research organization.
buyer: ASG, Inc.
ASG provides high-quality functional outsourcing and specialty staffing services to CROs, pharmaceutical, biotech and medical device companies that require clinical operations, GCP, GLP or GMP auditing, data management, statistical programming, biostatistics and medical writing solutions. "
target: Ockham Development Group, Inc.
Ockham Development Group Inc. is a privately held contract research organization headquartered in Cary, North Carolina.
price ($mm)
rev ($mm)
$12
EBITDA ($mm)
EV / rev
0.0x
EV / EBITDA
closed 4/22/2009 via BusinessWire

PPD, Inc., acquired AbCRO, Inc.

synopsis: PPD, Inc. announced that it has completed the acquisition of AbC.R.O., Inc., a Bulgarian contract research organization. The acquisition strengthens PPD’s ability to provide a broad range of clinical trial management and monitoring, patient recruitment, site identification and regulatory affairs services to its growing client base in the Balkans.
buyer: PPD, Inc.
PPD is a leading global contract research organization (CRO) providing discovery, development and post-approval services as well as compound partnering programs. PPD's clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. "
target: AbCRO, Inc.
AbCRO provides a full range of Phase II-IV clinical services, including clinical trial management and monitoring, patient recruitment, site identification and regulatory affairs.
price ($mm)
$36
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 3/20/2009 via PR Newswire

PharmaNet Development Group, Inc. merged with JLL Partners,

synopsis: JLL Partners, a leading private equity investment fund, and PharmaNet Development Group, Inc., a leading provider of clinical development services, announced the successful completion of the tender offer by JLL PharmaNet Holdings, LLC.
buyer: JLL Partners
Founded in 1988, JLL Partners is among the leading private equity investment firms in the country. Since inception, we have managed a series of private equity funds aggregating approximately $4 billion in committed capital. "
target: PharmaNet Development Group, Inc.
PharmaNet Development Group, Inc. is a leader in outsourced clinical development that offers clinical-development solutions including early and late stage consulting services, Phase I clinical studies and bioanalytical analyses, and Phase II, III and IV clinical development programs.
price ($mm)[EV]
$101 [$186]
rev ($mm)
$451
EBITDA ($mm)
$26
EV / rev
0.4x
EV / EBITDA
7.1x
closed 1/27/2009 via BusinessWire

Altarum Institute, acquired KAI Research, Inc.

synopsis: Altarum Institute, a non-profit health systems research and consulting organization, has purchased Rockville, Maryland-based KAI Research, Inc. (KAI). KAI provides innovative, cost-effective and practical support to the pharmaceutical and biotech industry, academic institutions and the National Institutes of Health.
buyer: Altarum Institute
Altarum Institute is a nonprofit health systems research and consulting organization serving government and private-sector clients. "
target: KAI Research, Inc.
KAI Research provides innovative, cost-effective and practical support to the pharmaceutical and biotech industries. KAI currently supports pharmaco-vigilance activities for over 90 marketed drugs and is providing safety surveillance for dozens of ongoing clinical trials.
price ($mm)
$7.55
rev ($mm)
$10
EBITDA ($mm)
EV / rev
0.8x
EV / EBITDA
closed 3/13/2009 via BNC Analysis

Premier Research Group, acquired Pivotal Research Centers, LLC

synopsis: PHC, Inc. d/b/a Pioneer Behavioral Health, a leading provider of inpatient and outpatient behavioral health services, announced Premier Research Arizona, LLC, a unit of Premier Research Group PLC, has signed a purchase agreement to acquire the assets of PHC's Pivotal Research Centers.
buyer: Premier Research Group
Premier Research is a leading solutions-driven CRO committed to therapeutic focus and operational expertise to deliver clinical trial services of the highest quality for biopharmaceutical and medical device companies. "
target parent: Pioneer Behavioral Health
target: Pivotal Research Centers, LLC
Pivotal Research Centers, LLC provides clinical drug testing. It performs all phases of clinical research for Phase I to Phase IV drugs under development through two research sites. Pivotal was founded by Louis C. Kirby in 1993 and is based in Phoenix, Arizona.
price ($mm)
$3.00
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 10/30/2007 via Company Press Release

Chiltern International Inc., acquired Clinical Trial Management Services, Inc.

synopsis: Chiltern, a leading global clinical research organization (CRO), announced the acquisition of Clinical Trial Management Services, Inc. (CTMS) a Bristol, Tennessee based CRO offering high quality services throughout the United States.
buyer: Chiltern International Inc.
Chiltern is a global CRO with experience running and staffing international Phase I to Phase IV clinical trials. Chiltern’s services include: Early Phase, Global Clinical Development, Late Phase, Biometrics, Medical and Regulatory Affairs and Resourcing Solutions. "
target: Clinical Trial Management Services, Inc.
Clinical Trial Management Services, Inc. provides clinical research services such as clinical trial management and monitoring services, such as project management, investigative site management and monitoring services.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 12/14/2009 via BusinessWire

NexMed, Inc., acquired Bio-Quant, Inc.

synopsis: NexMed, Inc., a developer of products based on the NexACT® technology, announced the closing of its acquisition of Bio-Quant, Inc., a privately-held leading research organization for in vitro and in vivo contract drug discovery and pre-clinical development services, headquartered in San Diego, CA.
buyer: NexMed, Inc. (NEXM:$0.00)
NexMed is an innovative drug developer that is leveraging its proprietary NexACT® drug delivery technology to produce a host of new medical treatments. NexMed’s drugs address a variety of health conditions, such as nail fungus, sexual disorders and more. "
target: Bio-Quant, Inc.
Founded in 1999, Bio-Quant is the largest specialty CRO based in San Diego and is one of the industry's most experienced CROs for in vitro and in vivo pharmacology services and research models specializing in oncology, inflammation, immunology, and metabolic diseases, including diabetes.
price ($mm)[EV]
$13 [$13]
rev ($mm)
$5
EBITDA ($mm)
EV / rev
2.5x
EV / EBITDA
announced 10/28/2009 via PR Newswire

Alpha Analytical, will acquire Boston Analytical

synopsis: Alpha Analytical is announcing the completion of the acquisition of Boston Analytical, Inc. Established in 1987, Boston Analytical is a registered, cGMP compliant contract testing laboratory providing quality analytical and microbiological testing services to the pharmaceutical, biotech, device, cosmetic and nutritional product industries.
buyer: Alpha Analytical
Alpha Analytical, Inc. provides full-service environmental laboratory solutions for the most demanding industrial and commercial applications in the U.S. and abroad. Alpha Analytical is the largest environmental laboratory in New England and among the top 18 laboratories in the country. "
target: Boston Analytical
Boston Analytical is committed to providing quality Analytical and Microbiological testing services to pharmaceutical companies worldwide in support of their Product Development, Release and Stability Testing objectives.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 10/12/2009 via Company Press Release

J O Hambro Capital Management Limited, acquired Celsis International

synopsis: Chicago-based Celsis International, a leading global life sciences company, announces that it has been acquired by UK-based private equity firm J O Hambro and will de-list from the London Stock Exchange (LSE) and operate as a privately held company.
buyer: J O Hambro Capital Management Limited
J O Hambro Capital Management, the London-based boutique investment firm, offers an alternative to the large traditional fund management firms that have dominated the market for many years. "
target: Celsis International
Celsis International plc is a leading international provider of innovative life science products and laboratory services to the pharmaceutical and consumer products industries through our three divisions: Rapid Detection, Analytical Services and In Vitro Technologies.
price ($mm)[EV]
$55 [$52]*
rev ($mm)
$42
EBITDA ($mm)
$12
EV / rev
1.9x
EV / EBITDA
6.3x
closed 7/16/2009 via PR Newswire

Water Street Healthcare Partners, acquired AAIPharma Services

synopsis: Water Street Healthcare Partners, a leading private equity firm focused exclusively on the health care industry, announced that it has acquired the Pharmaceutical Development division from AAIPharma Inc.
buyer: Water Street Healthcare Partners
Water Street Healthcare Partners is a leading private equity firm focused exclusively on health care. With more than $1 billion of capital under management, Water Street is one of the most active investors in the health care industry. "
target parent: AAIPharma Inc.
target: AAIPharma Services
AAIPharma Services serves more than 300 large pharmaceutical and biotechnology companies. Its team of 450 scientists and professionals specialize in services that encompass the entire process of pharmaceutical drug development from discovery through commercialization.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 6/1/2009 via Reuters

INC Research, Inc., will purchase Late Stage Research Unit from MDS, Inc.

synopsis: MDS Inc has announced that it planns to narrow its contract research focus by selling its late stage operations and central laboratory divisions to Contract Research Organization INC Research, Inc.
buyer: INC Research, Inc. (SYNH:$3,472.40)
INC Research is a therapeutically focused contract research organization with an unrivaled reputation for conducting Phase I- Phase IV clinical development programs of the highest integrity. "
seller: MDS, Inc. (MDZ:$231.00)
MDS Inc. is a global life sciences company that provides market-leading products and services that are used by its customers for the development of drugs, and the diagnosis and treatment of disease. The Company has more than 5,000 employees in 29 countries and net revenues of more than US$1.2 bil.
price ($mm)
$45
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 4/17/2009 via PR Newswire

ChemRar High-Tech Center, acquired Prudentas, LLC

synopsis: ChemDiv, a global chemistry-driven contract research organization, announced that its ChemRar High Tech Center has acquired Prudentas LLC, one of the leading CRO companies conducting high quality Phase I - Phase IV studies in Eastern Europe.
buyer parent: ChemDiv, Inc.
buyer: ChemRar High-Tech Center
The ChemRar High-Tech Center is a unique pharma and biotechnology complex founded by innovative life science organizations in Russia. ChemRar's component companies are engaged in discovering, developing and commercializing novel drugs for partners in Russia and worldwide. "
target: Prudentas, LLC
Prudentas is a Russian Clinical Contract Research Organization founded by and consisting of highly qualified clinical research professionals with extensive experience of working previously together as a team.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 8/16/2017 via BusinessWire

Evotec BioSystems GmbH, acquired Aptuit, Inc.

synopsis: Evotec announced that it has successfully completed the acquisition of Aptuit, a partner research organisation for integrated outsourced drug discovery and development solutions. This acquisition adds considerable business opportunities to further accelerate Evotec's long-term strategy to be the industry partner of choice for external innovation.
buyer: Evotec BioSystems GmbH (XTRA:EVT:$226.46)
Founded in Hamburg Germany, Evotec BioSystems GmbH is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. "
target parent: Welsh, Carson, Anderson & Stowe
target: Aptuit, Inc.
Aptuit, Inc. (formerly Global Pharmaceutical Development, Inc.) is an emerging company focused on streamlining and supporting the drug development process for biotechnology and pharmaceutical innovators.
price ($mm)
$300
rev ($mm)
$93
EBITDA ($mm)
$12
EV / rev
3.2x
EV / EBITDA
25.8x
closed 3/15/2006 via BusinessWire

Aptuit, Inc., acquired InfoPro Solutions, Inc.

synopsis: Aptuit, Inc. announced today that it has completed its acquisition of InfoPro Solutions and is launching Aptuit Informatics. The new business line will combine existing Aptuit resources with InfoPro Solutions' 120 employees and industry leading clinical informatics platforms and expertise.
buyer parent: Welsh, Carson, Anderson & Stowe
buyer: Aptuit, Inc.
Aptuit, Inc. (formerly Global Pharmaceutical Development, Inc.) is an emerging company focused on streamlining and supporting the drug development process for biotechnology and pharmaceutical innovators. "
target: InfoPro Solutions, Inc.
InfoPro Solutions has been developing, implementing and maintaining enterprise-class, mission-critical information systems for the drug development markets within the pharmaceutical and biotechnology industries.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 8/16/2017 via BusinessWire

Evotec BioSystems GmbH, acquired Aptuit, Inc.

synopsis: Evotec announced that it has successfully completed the acquisition of Aptuit, a partner research organisation for integrated outsourced drug discovery and development solutions. This acquisition adds considerable business opportunities to further accelerate Evotec's long-term strategy to be the industry partner of choice for external innovation.
buyer: Evotec BioSystems GmbH (XTRA:EVT:$226.46)
Founded in Hamburg Germany, Evotec BioSystems GmbH is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. "
target parent: Welsh, Carson, Anderson & Stowe
target: Aptuit, Inc.
Aptuit, Inc. (formerly Global Pharmaceutical Development, Inc.) is an emerging company focused on streamlining and supporting the drug development process for biotechnology and pharmaceutical innovators.
price ($mm)
$300
rev ($mm)
$93
EBITDA ($mm)
$12
EV / rev
3.2x
EV / EBITDA
25.8x
closed 8/16/2017 via BusinessWire

Evotec BioSystems GmbH, acquired Aptuit, Inc.

synopsis: Evotec announced that it has successfully completed the acquisition of Aptuit, a partner research organisation for integrated outsourced drug discovery and development solutions. This acquisition adds considerable business opportunities to further accelerate Evotec's long-term strategy to be the industry partner of choice for external innovation.
buyer: Evotec BioSystems GmbH (XTRA:EVT:$226.46)
Founded in Hamburg Germany, Evotec BioSystems GmbH is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. "
target parent: Welsh, Carson, Anderson & Stowe
target: Aptuit, Inc.
Aptuit, Inc. (formerly Global Pharmaceutical Development, Inc.) is an emerging company focused on streamlining and supporting the drug development process for biotechnology and pharmaceutical innovators.
price ($mm)
$300
rev ($mm)
$93
EBITDA ($mm)
$12
EV / rev
3.2x
EV / EBITDA
25.8x
closed 6/1/2005 via Company Press Release

Thomson Pharma, acquired Pharmaceutical Information Associates, Ltd.

synopsis: The Thomson Corporation announced that it has acquired Pharmaceutical Information Associates Ltd (PIA) and Astrolabe Analytica, Inc. (AAI). PIA and AAI are leading providers of regulatory consulting, marketing analytics and scientific communications services for the pharmaceutical industry.
buyer parent: The Thomson Corporation
buyer: Thomson Pharma
Thomson Pharma is a dynamic, information offering for the pharmaceutical and biotechnology industries that is being developed by Thomson Scientific. "
target: Pharmaceutical Information Associates, Ltd.
Since 1990, Pharmaceutical Information Associates has supported the global drug development process by assisting with regulatory strategy development, the preparation of regulatory documentation, and the design, conduct, and audit of specialized clinical studies.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 6/5/2018 via Company Press Release

JLL Partners, Water Street Healthcare Partners, acquired Triplefin

synopsis: Water Street Healthcare Partners, a strategic investor focused exclusively on the health care industry, and JLL Partners, a leading middle-market private equity firm, announced that they acquired Triplefin, an industry leader in patient support for more than 30 years.
buyer: JLL Partners
buyer: Water Street Healthcare Partners
Water Street is a strategic investor focused exclusively on health care. The firm has a strong record of building market-leading companies across key growth sectors in health care. JLL Partners is a leading middle-market private equity firm. "
target parent: H.D. Smith
target: Triplefin
A market leader in patient support for more than 30 years, Triplefin delivers comprehensive hub services that improve patient access and adherence, including its patent-pending Rx365® suite of digital solutions.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 3/27/2018 via Company Press Release

The WIRB-Copernicus Group, acquired ACI Clinical

synopsis: WIRB-Copernicus Group, the world’s leading provider of solutions that measurably improve the quality and efficiency of clinical research, has acquired ACI Clinical, a specialty provider of clinical trial committees and clinical trial advisory services.
buyer parent: Arsenal Capital Partners
buyer: The WIRB-Copernicus Group
WIRB-Copernicus Group (WCG) is the world's leading provider of solutions to measurably improve the quality and efficiency of clinical research. WCG enables biopharmaceutical companies, CROs and institutions to accelerate the delivery of new treatments and therapies to patients. "
target: ACI Clinical
ACI Clinical is a specialty provider of clinical trial committees and clinical trial advisory services. ACI Clinical specializes in clinical and safety consulting, including full service Endpoint Adjudication Committees and Data Monitoring Committees.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 4/15/2014 via BNC Analysis

Synchrogenix Information Strategies, Inc. merged with Certara,

synopsis: Arsenal Capital Partners have acquired Synchrogenix Information Strategies Inc., which will merge with Certara LP. Synchrogenix, a specialty contract research organization providing strategic regulatory writing and related services to pharmaceutical, biotechnology, and medical device companies worldwide.
buyer parent: Arsenal Capital Partners
buyer: Certara
Certara™ is dedicated to improving human health through a broad spectrum of software products and services, from molecular discovery through clinical development, with special focus on supporting translational approaches to drug development. "
target: Synchrogenix Information Strategies, Inc.
Synchrogenix is a specialty contract research organization providing strategic regulatory writing and related services to pharmaceutical, biotechnology, and medical device companies worldwide. The company offers pre-clinical, clinical, CMC, and drug safety writing and submission services.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 12/4/2013 via PR Newswire

Accelera Innovations, Inc., will acquire Behavioral Health Care Associates, Ltd.

synopsis: Accelera Innovations, Inc., a provider of cloud based software-as-a-service solutions to the healthcare industry announced that they have signed a stock purchase agreement to acquire 100% of Behavioral Health Care Associates, Ltd., a provider of billing, practice management and administrative services to doctors and other clinicians.
buyer: Accelera Innovations, Inc.
Accelera Innovations, Inc. offers cloud based software-as-a-service solutions to the healthcare industry that includes technology and services to providers and payers, who are seeking to create an interoperable technology platform that is patient-centric. "
target: Behavioral Health Care Associates, Ltd.
Behavioral Health Care Associates, Ltd. provides billing, practice management and administrative services to doctors and other clinicians who provide services to hospitals, nursing homes and individual clients.
price ($mm)
$4.55
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 10/21/2013 via BNC Analysis

DrugDev, acquired CFS Clinical

synopsis: DrugDev, an interactive network and data sharing platform for over 80,000 clinical trial doctors in 93 countries, announced its acquisition of CFS Clinical (CFS), the leading specialty provider focused on the business and financial management activities for clinical trials.
buyer: DrugDev
DrugDev helps the clinical trials industry run faster, cheaper and smarter trials. Experienced Investigators choose to be part of the free network to access new clinical trial opportunities they would not otherwise have learnt about. "
target: CFS Clinical
CFS Clinical (CFS) is a technology-enabled service provider focused on the business and financial management activities for clinical trials.CFS’ experts deliver best-in-class Investigator site payment and study startup solutions around the globe.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 6/20/2013 via PR Newswire

H.D. Smith, acquired Triplefin

synopsis: H. D. Smith, among the nation's largest pharmaceutical wholesalers, announced the completion of the deal to attain majority interest in Triplefin, a reimbursement, patient assistance and pharmaceutical brand-support services company, headquartered in Cincinnati, Ohio.
buyer: H.D. Smith
H. D. Smith is among the largest national full-line, full-service wholesalers providing a complete line of prescription products, OTCs, HBAs, home healthcare products, medical equipment, seasonal merchandise and an array of marketing programs to pharmacies, regional chains and health systems. "
target: Triplefin
Triplefin is recognized as the premier provider of pharmaceutical marketing support solutions. For more than 30 years, Triplefin has continually helped pharmaceutical brand managers remove barriers to brand access and adherence and put prescription brands into patients' hands.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 6/20/2012 via PR Newswire

ePharmaSolutions, Inc., acquired Polaris Biopharma Consulting

synopsis: ePharmaSolutions announced the acquisition of Polaris BioPharma Consulting, a leading global patient recruitment and retention firm headquartered in Slough, UK. Polaris Biopharma was founded in 1999 as a boutique patient recruitment and retention firm supporting global pharmaceutical companies.
buyer: ePharmaSolutions, Inc.
ePharmaSolutions is a leading provider of technology-based clinical services that helps improve the way sites are selected, trained, activated and managed to exceed enrollment goals. ePharmaSolutions won the 2009 Bio-IT World Award for best clinical trial technology. "
target: Polaris Biopharma Consulting
Polaris Biopharma Consulting is a boutique patient recruitment and retention firm. Polaris has helped large and mid-sized pharmaceutical companies and CROs develop and deploy hundreds of global feasibility, trial optimisation and patient recruitment programs in every major therapeutic area.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 6/13/2006 via BusinessWire

Applied Clinical Intelligence merged with TAKE Solutions, Inc.,

synopsis: TAKE Solutions, Inc. announced the formation of the OneClinical brand of life sciences offerings as part of its merger with Applied Clinical Intelligence and OnSphere Corporation. OneClinical combines a full spectrum of proven data and document management software products and services for clinical trials, drug and device development lifecycles.
buyer parent: Shriram Group
buyer: TAKE Solutions, Inc. (BSE:532890:$259.76)
TAKE Solutions is a leading international business technology company with products backed by a strong domain expertise to provide cost-effective comprehensive solutions for businesses. "
target: Applied Clinical Intelligence
Applied Clinical Intelligence was founded in 2001 to provide data-driven solutions for clinical trials and risk management programs. ACI is a specialized clinical services group offering strategic, operational, and technical intelligence.
price ($mm)
$4.71
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 11/30/2009 via BusinessWire

PPD, Inc., acquired BioDuro, LLC

synopsis: PPD, Inc. announced it has completed its acquisition of BioDuro LLC, a drug discovery outsourcing company focused on integrated drug discovery programs and services. With this acquisition, PPD now employs more than 1,400 in Asia Pacific and nearly 1,000 people in China.
buyer: PPD, Inc.
PPD is a leading global contract research organization (CRO) providing discovery, development and post-approval services as well as compound partnering programs. PPD's clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. "
target: BioDuro, LLC
BioDuro is a US-based, fully-integrated, end-to-end global life science outsourcing services company with a team of over 630 in Beijing, China. Our priority is providing the highest quality, FDA-compliant services at an affordable cost.
price ($mm)
$49
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 2/26/2009 via PR Newswire

ChanTest Corporation, acquired Applied Cell Sciences

synopsis: The leading experts in ion channels and G-protein coupled receptors - key to drug discovery, development, and safety - are now united. ChanTest, the leading provider of ion channel testing services and validated cell lines, announced that it has acquired Rockville, Maryland-based Applied Cell Sciences. ACS is a contract research organization.
buyer: ChanTest Corporation
ChanTest has developed the world’s most complete library of validated human ion channel-expressing cell lines to serve all the ion channel needs of its pharmaceutical and biotech customers. "
target: Applied Cell Sciences
Applied Cell Sciences delivers high throughput screening reagents and reagent-development services for drug discovery research.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 2/6/2009 via BusinessWire

WIL Research Laboratories, LLC, acquired Midwest BioResearch, LLC

synopsis: WIL Research Laboratories, LLC and WIL Research Holding Company, Inc. announce the acquisition of Midwest BioResearch, LLC. Together, Midwest BioResearch and WIL Research shall integrate their service offerings through scientific collaboration, sharing of best practices and marketing.
buyer: WIL Research Laboratories, LLC
WIL Research Laboratories, LLC is a contract research organization that provides an interdisciplinary approach to non-clinical toxicology, pharmacology, metabolism and both clinical and non-clinical bioanalytical services. "
target: Midwest BioResearch, LLC
Midwest BioResearch, LLC was founded in 2003 by scientists, directors and managers from major pharmaceutical companies to provide drug disposition and toxicology services.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 11/13/2007 via PR Newswire

Cegedim Group S.A., acquired 3ES

synopsis: Cegedim Strategic Data, leading provider of Pharmaceutical Market Research has completed its acquisition of 3ES, a CRO member of the AFCRO, specializing in Clinical Studies and post-AMM studies, notably through online tools.
buyer: Cegedim Group S.A. (ENXTPA:CGM:$512.82)
Established as the world's leading CRM provider for the life sciences industry with its Cegedim Dendrite business unit, CEGEDIM provides the world's largest pharmaceutical companies with vital support for successful Customer Relationship Management (CRM). "
target: 3ES
3ES provides multidisciplinary expertise in the medical research field. 3ES has developed their in-house software for managing online studies via Internet, and has received the ANVAR label for "innovating business".
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 8/28/2012 via BNC Analysis

United Drug plc, will acquire Drug Safety Alliance, Inc.

synopsis: Irish healthcare services provider United Drug plc announced an agreement to acquire North Carolina based Drug Safety Alliance Inc. DSA is a global leader in safety and risk management services supporting pharmaceutical, biotech, medical device, consumer health and animal health organizations.
buyer: United Drug plc (LSE:UDG:$1,298.52)
United Drug is a leading international healthcare services provider, employing 6,000 people in 35 businesses across Europe and the US. United Drug operates through 4 divisions. United Drug is a provider of services to pharmaceutical retailers and manufacturers. "
target: Drug Safety Alliance, Inc.
Drug Safety Alliance, Inc. is a provider of clinical trial and post-marketing drug safety and pharmacovigilance solutions to the pharmaceutical and biotech industries. DSA manages services including case management, regulatory consulting, quality management, and a secure, validated safety database.
price ($mm)
$21
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 9/26/2012 via BusinessWire

Accenture, acquired Octagon Research Solutions, Inc.

synopsis: Accenture completed its acquisition of Octagon Research Solutions, a provider of clinical and regulatory information management solutions and software for the pharmaceutical industry. The acquisition enhances Accenture's existing clinical services capabilities – including clinical data management, clinical programming and safety case processing.
buyer: Accenture (ACN:$44,655.80)
Accenture is a global management consulting, technology services and outsourcing company. Accenture collaborates with clients to help them become high performance businesses and governments. "
target parent: Edison Ventures
target: Octagon Research Solutions, Inc.
Octagon Research Solutions is the world leader in clinical and regulatory information management solutions to the life sciences industry. Through an integrated suite of outsourced services, strategic consulting, and innovative technology, Octagon optimizes the entire drug development lifecycle.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 4/3/2012 via BusinessWire

Dohmen Company, acquired BioSoteria, Inc.

synopsis: The Dohmen Company has acquired BioSoteria, a leading provider of drug safety and risk management services to the biopharmaceutical industry. The BioSoteria management team has experience building drug safety departments from the ground up at start-up companies and expanding pharmacovigilance capabilities for larger companies.
buyer: Dohmen Company
Dohmen is a provider of outsourced business services. Dohmen’s portfolio of service offerings includes outsourced business services to life science manufacturers through DDN, and benefit management services to life science payers through RESTAT. "
target: BioSoteria, Inc.
BioSoteria provides a broad range of drug safety services to the biopharmaceutical industry. BioSoteria helps companies manage the safety of their products with a regulatory-compliant, best-practices approach. Being a trusted pharmacovigilance service provider begins with leadership.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 3/24/2004 via Reuters

AdvancePCS merged with Caremark Rx Inc,

synopsis: Caremark Rx, Inc. (NYSE: CMX), one of the nation's leading pharmaceutical services companies, and AdvancePCS (Nasdaq: ADVP), the nation's leading health improvement company, today announced the signing of a definitive merger agreement. The transaction is valued at approximately $6 billion and creates a company with a market capitalization of $13 B.
buyer: Caremark Rx Inc (CVS:$123,133.00)
Caremark Rx, Inc., a Delaware Corporation, is one of the largest pharmaceutical services companies in the United States, with net revenue of approximately $6.81 billion for 2002. The Company's operations are conducted through Caremark Inc., which provides pharmacy benefit management services and th "
target: AdvancePCS
Just when you thought the paradigm couldn't get more advanced, Advanced Paradigm and PCS Health Systems came together to form AdvancePCS. The company provides pharmacy and health management services for health plans covering more than 75 million members. AdvancePCS offers mail-order pharmacy progra
price ($mm)
$6,147
rev ($mm)
$14,680
EBITDA ($mm)
$393
EV / rev
0.4x
EV / EBITDA
15.7x
closed 11/16/2012 via PE Hub

Dowden Health Media, Inc., acquired QD Healthcare Group

synopsis: High Road Capital Partners announced its portfolio company Dowden Health Media has completed the acquisition of QD Healthcare Group, a Connecticut-based medical communications firm that provides scientific content development, promotional medical education and related marketing services to the pharmaceutical and biotechnology industries.
buyer parent: High Road Capital Partners
buyer: Dowden Health Media, Inc.
Dowden Health Media, Inc. is a provider of promotional medical education communication services through Medical Decision Point, LLC and Convergent Health Solutions, LLC; and eCrossings Media. DMCG is headquartered in Montvale, New Jersey. "
target: QD Healthcare Group
QD Healthcare Group provides scientific content development, promotional medical education and related marketing services to the pharmaceutical and biotechnology industries. QD Healthcare Group was founded in 1999 by Nick Kiratsous and Bradley Mock and is located in Stamford, Connecticut.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 5/22/2007 via PR Newswire

AMN Healthcare Services, Inc., acquired Rx Pro Health, Inc.

synopsis: AMN Healthcare Services, Inc. the nation's largest healthcare staffing company, is pleased to announce the acquisition of Rx Pro Health, Inc. and Pharmacy Choice, Inc., leading providers of pharmacy staffing, workforce technology solutions, and on-line educational services for hospital-based and retail pharmacies and pharmaceutical companies.
buyer: AMN Healthcare Services, Inc. (AHS:$2,163.85)
AMN Healthcare Services, Inc. is a leading temporary healthcare staffing company and is the largest nationwide provider of travel nurse staffing services. The company recruits nurses and allied health professionals, our “temporary healthcare professionals,” nationally and internationally. "
target: Rx Pro Health, Inc.
Rx Pro Health, Inc. is a leading provider of pharmacy staffing, workforce technology solutions, and on-line educational services for hospital-based and retail pharmacies and pharmaceutical companies.
price ($mm)
$17
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA

Like Aptuit, Inc.


read more

Aptuit, Inc.

Invicro, LLC

PAREXEL International Corporation

inVentiv Health, Inc.

Quintiles Transnational Corp.

Excel PharmaStudies Inc.

Encorium Group Inc.

Clinical Trials of the Americas, Inc.

Ockham Development Group, Inc.

AbCRO, Inc.

PharmaNet Development Group, Inc.

KAI Research, Inc.

Pivotal Research Centers, LLC

Clinical Trial Management Services, Inc.

Bio-Quant, Inc.

Boston Analytical

Celsis International

AAIPharma Services

MDS, Inc.

Prudentas, LLC

read more

Aptuit, Inc.

InfoPro Solutions, Inc.

read more

Aptuit, Inc.

read more

Aptuit, Inc.

Pharmaceutical Information Associates, Ltd.

Triplefin

ACI Clinical

Synchrogenix Information Strategies, Inc.

Behavioral Health Care Associates, Ltd.

CFS Clinical

Triplefin

Polaris Biopharma Consulting

Applied Clinical Intelligence

BioDuro, LLC

Applied Cell Sciences

Midwest BioResearch, LLC

3ES

Drug Safety Alliance, Inc.

Octagon Research Solutions, Inc.

BioSoteria, Inc.

AdvancePCS

QD Healthcare Group

Rx Pro Health, Inc.

Geography
Matching Companies
Ticker: SYNH
 
 
 
 
 
 
 
 
INC Research, Inc.
INC Research, Inc.
INC Research is a leading global contract research organization ("CRO") providing the full range of Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries.
year
2018
rev ($mm)
$3,472.40
EBITDA ($mm)
$441.82
EBIT ($mm)
$157.52
Net Income ($mm)
Employees
21000
  • drill down
  • watch
Ticker: ICLR
 
 
 
 
 
 
 
 
ICON Plc
ICON Plc
ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company specialises in the strategic development, management and analysis of programs that support clinical development.
year
2015
rev ($mm)
$1,541.91
EBITDA ($mm)
$289.74
EBIT ($mm)
$234.82
Net Income ($mm)
$192.14
Employees
11200
  • drill down
  • watch
Ticker:
 
 
 
 
 
 
 
 
CMIC Co., Ltd.
CMIC is a leading full-service CRO in Japan offering a wide range of services in clinical trials in Asia to both multi-national and Japanese pharma companies.
year
2019
rev ($mm)
$664.65
EBITDA ($mm)
$76.21
EBIT ($mm)
$43.15
Net Income ($mm)
$23.12
Employees
4962
  • drill down
  • watch
Ticker: PIELF
 
 
 
 
 
 
 
 
Pierrel SpA
Pierrel SpA
Pierrel S.p.A. is a pharmaceutical company specializing in contract research, development and the manufacture of medicines. The Pierrel Group boasts over 50 years of experience in the pharmaceutical sector, and is one of the main Italian manufacturers of local anaesthetics for dental use.
year
2008
rev ($mm)
$64.38
EBITDA ($mm)
($4.23)
EBIT ($mm)
($8.92)
Net Income ($mm)
Employees
504
  • drill down
  • watch
Ticker: ENCO
 
 
 
 
 
 
 
 
Encorium Group Inc.
Encorium is a full-service Contract Research Organization providing comprehensive solutions for pharmaceutical, biotechnology, and medical device companies. At Encorium we recognize the challenges that often arise during drug development.
year
2008
rev ($mm)
$35.91
EBITDA ($mm)
($5.19)
EBIT ($mm)
($6.89)
Net Income ($mm)
Employees
226
  • drill down
  • watch
Ticker: ENXTPA:ERF
 
 
 
 
 
 
 
 
Eurofins Group
Eurofins Group
Based in Luxembourg, Eurofins is a leading international group of laboratories providing a unique range of analytical testing services to the pharmaceutical, food, environmental and consumer products industries and to governments.
year
2017
rev ($mm)
$3,467.64
EBITDA ($mm)
$637.81
EBIT ($mm)
$406.82
Net Income ($mm)
$252.97
Employees
34651
  • drill down
  • watch
Ticker: CRL
 
 
 
 
 
 
 
 
Charles River Laboratories International Inc.
Charles River Laboratories International Inc.
Charles River has been helping our global partners accelerate drug discovery and development by providing them with tailored research models and preclinical, clinical, support services.
year
2009
rev ($mm)
$1,202.55
EBITDA ($mm)
$282.48
EBIT ($mm)
$188.93
Net Income ($mm)
$114.44
Employees
8000
  • drill down
  • watch
Ticker: LH
 
 
 
 
 
 
 
 
LabCorp
LabCorp provides leading-edge medical laboratory tests and services through a national network of primary clinical laboratories and specialty testing laboratories. LabCorp processes tests on approximately 470,000 specimens each day, applying advances in medicine and science to laboratory testing.
year
2009
rev ($mm)
$4,694.70
EBITDA ($mm)
$1,142.70
EBIT ($mm)
$949.40
Net Income ($mm)
$543.30
Employees
28000
  • drill down
  • watch
Ticker: XTRA:EVT
 
 
 
 
 
 
 
 
Evotec BioSystems GmbH
Founded in Hamburg Germany, Evotec BioSystems GmbH is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists.
year
2017
rev ($mm)
$226.46
EBITDA ($mm)
$53.38
EBIT ($mm)
$38.55
Net Income ($mm)
$40.69
Employees
1316
  • drill down
  • watch
Ticker: WX
 
 
 
 
 
 
 
 
WuXi AppTec
WuXi AppTec
WuXi AppTec is a leading global pharmaceutical, biopharmaceutical, and medical device open-access capability and technology platform with operations in China and the United States. WuXi AppTec provides a broad and integrated portfolio of services throughout the drug R&D process.
year
2014
rev ($mm)
$640.80
EBITDA ($mm)
$155.57
EBIT ($mm)
$108.53
Net Income ($mm)
$112.01
Employees
7445
  • drill down
  • watch
Ticker: AIM:C4XD
 
 
 
 
 
 
 
 
C4X Discovery
C4X Discovery aims to become the world’s most productive drug discovery and development company by exploiting cutting-edge technologies to design and create best-in-class drug candidates.
year
2015
rev ($mm)
$0.44
EBITDA ($mm)
($5.46)
EBIT ($mm)
($5.50)
Net Income ($mm)
Employees
19
  • drill down
  • watch
Ticker: BSE:532890
 
 
 
 
 
 
 
 
TAKE Solutions, Inc.
TAKE Solutions, Inc.
TAKE Solutions delivers domain-intensive services in Life Sciences and Supply Chain Management. Their range of services span from clinical trials to regulatory submissions to post-marketing safety, all backed by insights derived through proprietary industry networks forums.
year
2018
rev ($mm)
$259.76
EBITDA ($mm)
$39.17
EBIT ($mm)
$33.43
Net Income ($mm)
$28.24
Employees
1500
  • drill down
  • watch
Ticker: MCK
 
 
 
 
 
 
 
 
McKesson Corporation
McKesson Corporation
McKesson Corporation is a healthcare services and information technology company dedicated to making the business of healthcare run better. McKesson partners with payers, hospitals, physician offices, pharmacies, pharmaceutical companies and others across the spectrum of care.
year
2019
rev ($mm)
$214,319.00
EBITDA ($mm)
$4,229.00
EBIT ($mm)
$3,280.00
Net Income ($mm)
$34.00
Employees
70000
  • drill down
  • watch
Ticker: SYNH
 
 
 
 
 
 
 
 
INC Research, Inc.
INC Research, Inc.
INC Research is a leading global contract research organization ("CRO") providing the full range of Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries.
year
2018
rev ($mm)
$3,472.40
EBITDA ($mm)
$441.82
EBIT ($mm)
$157.52
Net Income ($mm)
Employees
21000
  • drill down
  • watch
Ticker: ICLR
 
 
 
 
 
 
 
 
ICON Plc
ICON Plc
ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company specialises in the strategic development, management and analysis of programs that support clinical development.
year
2015
rev ($mm)
$1,541.91
EBITDA ($mm)
$289.74
EBIT ($mm)
$234.82
Net Income ($mm)
$192.14
Employees
11200
  • drill down
  • watch
Ticker:
 
 
 
 
 
 
 
 
CMIC Co., Ltd.
CMIC is a leading full-service CRO in Japan offering a wide range of services in clinical trials in Asia to both multi-national and Japanese pharma companies.
year
2019
rev ($mm)
$664.65
EBITDA ($mm)
$76.21
EBIT ($mm)
$43.15
Net Income ($mm)
$23.12
Employees
4962
  • drill down
  • watch
Ticker: PIELF
 
 
 
 
 
 
 
 
Pierrel SpA
Pierrel SpA
Pierrel S.p.A. is a pharmaceutical company specializing in contract research, development and the manufacture of medicines. The Pierrel Group boasts over 50 years of experience in the pharmaceutical sector, and is one of the main Italian manufacturers of local anaesthetics for dental use.
year
2008
rev ($mm)
$64.38
EBITDA ($mm)
($4.23)
EBIT ($mm)
($8.92)
Net Income ($mm)
Employees
504
  • drill down
  • watch
Ticker: ENCO
 
 
 
 
 
 
 
 
Encorium Group Inc.
Encorium is a full-service Contract Research Organization providing comprehensive solutions for pharmaceutical, biotechnology, and medical device companies. At Encorium we recognize the challenges that often arise during drug development.
year
2008
rev ($mm)
$35.91
EBITDA ($mm)
($5.19)
EBIT ($mm)
($6.89)
Net Income ($mm)
Employees
226
  • drill down
  • watch
Ticker: ABC
 
 
 
 
 
 
 
 
AmerisourceBergen Corporation
AmerisourceBergen Corporation
AmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care. Tens of thousands of healthcare providers, veterinary practices and livestock producers trust them as their partner in the pharmaceutical supply chain.
year
2019
rev ($mm)
$175,151.50
EBITDA ($mm)
$2,276.42
EBIT ($mm)
$1,735.61
Net Income ($mm)
$929.88
Employees
20500
  • drill down
  • watch
Ticker: ADRX
 
 
 
 
 
 
 
 
Andrx Corporation
Andrx Corporation is committed to providing: high quality, cost effective pharmaceuticals to our customers and to patients; sustained profit and revenue growth to our stockholders; and an employee culture that is stimulating and rewarding.
year
2005
rev ($mm)
$1,145.10
EBITDA ($mm)
$132.00
EBIT ($mm)
$95.90
Net Income ($mm)
$65.70
Employees
0
  • drill down
  • watch
Ticker: MDZ
 
 
 
 
 
 
 
 
MDS, Inc.
MDS Inc. is a global life sciences company that provides market-leading products and services that are used by its customers for the development of drugs, and the diagnosis and treatment of disease. The Company has more than 5,000 employees in 29 countries and net revenues of more than US$1.2 bil.
year
2009
rev ($mm)
$231.00
EBITDA ($mm)
$37.00
EBIT ($mm)
$13.00
Net Income ($mm)
Employees
3600
  • drill down
  • watch
Ticker: ABPI
 
 
 
 
 
 
 
 
Accentia Biopharmaceuticals, Inc.
Accentia Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the development of Revimmune as a system of care for the treatment of autoimmune diseases. The company, through its subsidiary, Biovest International, Inc.
year
2012
rev ($mm)
$4.05
EBITDA ($mm)
($11.29)
EBIT ($mm)
($11.54)
Net Income ($mm)
Employees
54
  • drill down
  • watch
Ticker: CRL
 
 
 
 
 
 
 
 
Charles River Laboratories International Inc.
Charles River Laboratories International Inc.
Charles River has been helping our global partners accelerate drug discovery and development by providing them with tailored research models and preclinical, clinical, support services.
year
2009
rev ($mm)
$1,202.55
EBITDA ($mm)
$282.48
EBIT ($mm)
$188.93
Net Income ($mm)
$114.44
Employees
8000
  • drill down
  • watch